人乳头瘤病毒疫苗的研究进展
岳磊;井申荣;魏云林;
摘要(Abstract)：
宫颈癌是全球妇女恶性肿瘤中仅次于乳腺癌的第二种最常见的恶性肿瘤。人乳头瘤病毒(Human papillo-mavirus,HPV)与宫颈癌的发生密切相关,利用分子生物学方法构建的HPV疫苗对宫颈癌具有预防和治疗作用。目前,HPV疫苗的研究得到了迅速发展,并涌现出许多新的开发策略。本文对HPV疫苗的研究进展和前景作一综述。
关键词(KeyWords)： 宫颈癌;人乳头瘤病毒;疫苗
基金项目(Foundation): 国家“863”计划重大项目(2006AA02A227)
作者(Authors): 岳磊;井申荣;魏云林;
DOI: 10.13200/j.cjb.2008.04.92.yuel.026
参考文献(References)：
- [1]Saslow D,Castle PE,Cox JT,et al.American Cancer Society Guidelinefor human papillomavirus(HPV)vaccine use to prevent cervical cancerand its precursors.CA Cancer J Clin,2007,57(1):7-28.
- [2]Walboomers JM,Jacobs MV,Manos MM,et al.Human papillomavirus is anecessary cause of invasive cervical cancer worldwide.J Pathol,1999,189(1):12-19.
- [3]Kirnbauer R,Taub J,Greenstone H,et al.Efficient self-assembly of hu-man papillomavirus type 16 L1 and L1-L2 into virus-like particles.J Vi-rol,1993,67(12):6929-6936.
- [4]Schiller JT,Lowy DR.Papillomavirus-like particle based vaccines:cervi-cal cancer and beyond.Expert Opin Biol Ther,2001,1(4):571-581.
- [5]Harro CD,Pang YY,Roden RB,et al.Safety and immunogenicity trial inadult volunteers of a human papillomavirus 16 L1 virus-like particle vac-cine.J Natl Cancer Inst,2001,93(4):284-292.
- [6]Pinto LA,Edwards J,Castle PE,et al.Cellular immune responses to hu-man papillomavirus(HPV)-16 L1 in healthy volunteers immunized withrecombinant HPV-16 L1 virus-like particles.J Infect Dis,2003,188(2):327-338.
- [7]Koutsky LA,Ault KA,Wheeler CM,et al.A controlled trial of a humanpapillomavirus type 16 vaccine.N Engl J Med,2002,347(21):1645-1651.
- [8]Harper DM,Franco EL,Wheeler C,et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirustypes 16 and 18 in young women:a randomised controlled trial.Lancet,2004,364(9447):1757-1765.
- [9]Villa LL,Costa RL,Petta CA,et al.Prophylactic quadrivalent human pa-pillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine inyoung women:a randomised double-blind placebo-controlled multicentrephase II efficacy trial.Lancet Oncol,2005,6(5):271-278.
- [10]HPV疫苗研究进展.2006,http://www.china-obgyn.net/Article/Class3/Class6 cin/news/200610/1675.html.
- [11]抗HPV疫苗谋求全球受益.2007,http://www.chinapharm.com.cn/html/scfx/1175134377843.html.
- [12]针对宫颈癌进行预防接种.2007,http://www.moh.gov.cn/new-shtml/18101.htm.
- [13]李昂,郑瑾,来宝长,等.人乳头瘤病毒18型L1-E6、L1-E7嵌合基因表达载体的构建及表达.细胞与分子免疫学杂志,2002,18(6):558~561.
- [14]卢翌,卞继峰,于修平,等.HPV16L1E7的基因克隆及其在大肠杆菌中的表达.山东大学学报,2003,41(2):112-115.
- [15]Steller MA.Human papillomavirus,it’s genes...and cancer vaccines.Cancer Cell,2003,3(1):7-8.
- [16]Billich A.HPV vaccine MedImmune/GlaxoSmithKline.Curr Opin In-vestig Drugs,2003,4(2):210-213.
- [17]Brinkman JA,Xu X,Kast WM.The efficacy of a DNA vaccine contain-ing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors.Vaccine,2007,25(17):3437-3444.
- [18]Dawn K,Reichenbach,Jian Y.Efficacy of a novel engineered HPV-16plasmid DNA vaccine encoding a E6/E7 fusion gene.in AACR 2006.
- [19]Ramshaw IA,Ramsay AJ.The prime-boost strategy:exciting prospectsfor improved vaccination.Immunol Today,2000,21(4):163-165.
- [20]李鼎锋,刘勇,孙茂盛.初免-加强免疫策略在疫苗研究中的应用.微生物学免疫学进展,2006,34(3):65~68.
- [21]Berzofsky JA,Ahlers JD,Belyakov IM.Strategies for designing and opti-mizing new generation vaccines.Nat Rev Immunol,2001,1(3):209-219.